Sanofi, Regeneron put potential $5B in sales on the horizon with new PhIII dupilumab data

Partners Sanofi ($SNY) and Regeneron ($REGN) now have data in hand proving their atopic dermatitis candidate drug dupilumab can top placebo in clearing skin, reducing itching, and upping quality of life and mental health. The next step? Putting that data in to a regulatory package that the pair intends to submit to the FDA in the third quarter of this year. And if regulators are game, some optimistic analysts predict annual sales could soar up to $5 billion per year. More from FiercePharmaMarketing

Suggested Articles

A Missouri jury in 2017 ordered Johnson & Johnson to pay $110 million to plaintiff Lois Slemp, but now the verdict has been overturned.

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.